Neuroendocrine Tumors
Conditions
Keywords
NEN-neuroendocrine cancer, overall survival, OS - overall survival, PFS - progression-free survival
Brief summary
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, imaging, biochemical disease progression and no standard method of treatment hormone overproduction symptoms. The data of patients with advanced NEN with histopathological confirmation is collected from medical records. The progression-free survival (PFS), overall survival (OS) and influence of various factors on survival will be estimated. The research will be conducted for above 3 years on planned group 1500 patients. The aim of the study is to estimate median OS and PFS in advanced NEN patients treated with different schedule of systemic treatment.
Detailed description
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, imaging, biochemical disease progression and no standard method of treatment hormone overproduction symptoms. Systemic treatment including: somatostatin receptor analogues, molecular targeted therapy (sunitinib and everolimus), chemotherapy and peptide radioisotope therapy (Peptide Receptor Radionuclide Therapy). The data of patients with advanced NEN with histopathological or/and clinical or/and biochemical confirmation is collected from medical records. Neuroendocrine cancer from digestive system, respiratory system and another rarely occurring cancer including cancer connected with genetic syndromes like: MEN1, MEN2, VHL, NF1, SDHx will be included. The progression-free survival (PFS), overall survival (OS) and influence of various factors on survival will be estimated. Analyzed factors: age, sex, ethnicity, specific symptoms at the time of diagnosis, carcinoid heart disease, level of 5HIAA in DZM, level of CgA, liver test, size of tumor, cell differentiation of tumor based on Ki-67 index, liver metastases. The research will be conducted for above 3 years since July 2019 till December 2022 on planned group 1500 patients. The aim of the study is to estimate median OS and PFS in advanced NEN patients treated with different schedule of systemic treatment. The second goal is to create clinical practice recommendation based on potential prognostic factors of OS and PFS due to type of therapy in different NEN subgroups.
Interventions
None listed
Sponsors
University of Warmia and Mazury
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 87 Years
Healthy volunteers
No
Inclusion criteria
* Adults ≥18 years old, male or female, * Patients with histopathological confirmation of advanced neuroendocrine cancer (NEN), * Patients with NETG1, NETG2 based on Ki-67, * Patients with diagnosed NEN, who did not receive prior treatment and were qualified to systemic treatment, * Patients with advanced NEN who previously received first-line systemic therapy or second-line systemic therapy, * Patients with advanced, inoperable NEN cancer before the treatment, during the treatment and after the treatment regardless of lines of systemic therapy, * Patients with diagnosed NEN and performance status (PS) ≤3 according to ECOG/WHO classification, who received systemic therapy.
Exclusion criteria
* Patients without histopathological confirmation of neuroendocrine carcinoma (NEN), * Patients with diagnosed another type of cancer or benign tumor confirmed in histopathological examination, * Patients treated prior with intention to treat (ITT), * Patients with residual disease in further clinical follow-up without active systemic treatment, * Patients with advanced, progressive and poor performance status, who were disqualified from further systemic treatment, * Patients, who finished treatment during first month or their further disease process was unknown.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS - Progression Free Survival | 7 years | the time from the start of systemic treatment date to the date of first documented disease progression (event: disease progression - DP, based on RECIST, death, adverse events, which provide to disqualification from further therapy). Patients without progression at the time of analysis will be censored. |
| OS - Overall Survival | 7 years | is defined as the time from the start of systemic treatment date to the date of death due to any cause or the date of last contact (censored observation) at the date of data cut-off. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Log-rank test | 7 years | assessment of differences in survival of patients between subgroups |
| Cox proportional-hazards model | 7 years | uni- and multivariate analyses used for investigating the association between the survival time of patients and prognostic factors |
Countries
Poland
Contacts
Primary ContactJarosław B Ćwikła, MD, PhD
Outcome results
None listed